Stem cell therapy for heart disease

Journal of General Internal Medicine

Volumn 28, Issue 10, 2013, Pages 1353-1363

  Puliafico, Shannon B ^a,b   Penn, Marc S ^a,b,c   Silver, Kevin H ^a,b  

^a Northeast Ohio Cardiovascular Specialists   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

heart failure; myocardial infarction; paracrine; stem cell; ventricular function

Indexed keywords

ACUTE HEART INFARCTION; ADIPOSE DERIVED STEM CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CONGESTIVE CARDIOMYOPATHY; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; ENGRAFTMENT; HEALTH CARE PERSONNEL; HEALTH CARE PRACTICE; HEART FAILURE; HEART FUNCTION; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATIENT SAFETY; REVIEW; STEM CELL TRANSPLANTATION;

CLINICAL TRIALS AS TOPIC; GRAFT SURVIVAL; HEART DISEASES; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; PARACRINE COMMUNICATION; STEM CELL TRANSPLANTATION;

EID: 84885184131     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2508-z     Document Type: Review

References (101)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation. 2012;125:e2-220.
2. Jezierska-Wozniak K, Mystkowska D, Tutas A, Jurkowski MK. Stem cells as therapy for cardiac disease-a review. Folia Histochem Cytobiol. 2011;49:13-25.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-72. (Pubitemid 20119612)
4. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation. 1999;100:2054-9. (Pubitemid 29532055)
5. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009;53:13-20.
6. Rosenstrauch D, Poglajen G, Zidar N, Gregoric ID. Stem cell therapy for ischemic heart failure. Tex Heart Inst J. 2005;32:339-47. (Pubitemid 41306790)
7. Flynn A, O'Brien T. Stem cell therapy for cardiac disease. Expert Opin Biol Ther. 2011;11:177-87.
8. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344:1750-7. (Pubitemid 32497029)
9. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-5. (Pubitemid 32290358)
10. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res. 2003;92:139-50. (Pubitemid 36254270)
11. Strauer BE, Schannwell CM, Brehm M. Therapeutic potentials of stem cells in cardiac diseases. Minerva Cardioangiol. 2009;57:249-67.
12. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med. 2007;167:989-97. (Pubitemid 46835786)
13. Lipinski MJ, Biondi-Zoccai GG, Abbate A, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol. 2007;50:1761-7. (Pubitemid 47600592)
14. Kuswardhani RA, Soejitno A. Bone marrow-derived stem cells as an adjunctive treatment for acute myocardial infarction: A systematic review and meta-analysis. Acta Med Indones. 2011;43:168-77.
15. Shiba Y, Hauch KD, Laflamme MA. Cardiac applications for human pluripotent stem cells. Curr Pharm Des. 2009;15:2791-806.
16. Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med. 2009;11:1-19.
17. Singla DK, Hacker TA, Ma L, et al. Transplantation of embryonic stem cells intro the infarcted mouse heart: formation of multiple cell types. J Mol Cell Cardiol. 2006;40:195-200. (Pubitemid 43012130)
18. Wu KH, Zhou B, Yu CT, et al. Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann Thorac Surg. 2007;83:1491-8. (Pubitemid 46454258)
19. Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart disease. Br Med Bull. 2011;98:143-59.
20. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-76. (Pubitemid 37186770)
21. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003;100:12313-8. (Pubitemid 37271557)
22. Wei HM, Wong P, Hsu LF, Shim W. Human bone marrow-derived adult stem cells for post-myocardial infarction cardiac repair: current status and future directions. Singapore Med J. 2009;50:935-42.
23. Krause K, Schneider C, Kuck KH, Jaquet K. Review: stem cell therapy in cardiovascular disorders. Cardiovas Ther. 2010;28:e101-10.
24. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:208-16. (Pubitemid 351161191)
25. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 2005;102:11474-9. (Pubitemid 41153844)
26. Van't Hof W, Mal N, Huang Y, et al. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy. 2007;9:477-87. (Pubitemid 47386685)
27. Penn MS, Ellis S, Gandhi S, et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: Phase I clinical study. Circ Res. 2012;110:304-11.
28. Wu KH, Mo XM, Han ZC, Zhou B. Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg. 2011;92:1917-25.
29. Strauer BE, Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart from the methodological origin to clinical practice. J Am Coll Cardiol. 2011;58:1095-104.
30. Suzuki K, Murtuza B, Beauchamp JR, et al. Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. FASEB J. 2004;18:1153-5. (Pubitemid 39561554)
31. ter Horst KW. Stem cell therapy for myocardial infarction: Are we missing time? Cardiology. 2010;117:1-10.
32. Kupatt C, Hinkel R, Lamparter M, et al. Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT Kinase. Circulation. 2005;112:I-117-22.
33. Askari AT, Unzek S, Popvic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:697-703. (Pubitemid 37101067)
34. Nygren J, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004;10:494-501. (Pubitemid 38667908)
35. Penn MS, Mayorga ME. Searching for understanding with the cellular lining of life. Circ Res. 2010;106:1554-6.
36. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-19.
37. Penn MS, Dong F, Klein S, Mayora ME. Stem cells for myocardial regeneration. Clin Pharm Ther. 2011;90:499-501.
38. Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res. 2006;98:1414-21. (Pubitemid 43948066)
39. Ceradini DJ, Kulkarni AR, Callagan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-64. (Pubitemid 39070860)
40. Yamaguchi J, Kusano KF, Mauo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endoethlial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322-8. (Pubitemid 36314418)
41. Penn MS. Importance of the SDF-1: CXCR4 axis in myocardial repair. Circ Res. 2009;104:1133-5.
42. Zhang M, Mal N, Kiedrowski M, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007;21:3197-207.
43. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-8. (Pubitemid 35176294)
44. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:3009-17. (Pubitemid 35440281)
45. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol. 2004;44:1690-9. (Pubitemid 39369805)
46. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-8. (Pubitemid 38891685)
47. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. American Journal of Cardiology. 2004;94:92-5. (Pubitemid 38813459)
48. Fernandez-Aviles F, San Roman JA, Garcia-Frade J, et al. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res. 2004;95:742-8. (Pubitemid 39331935)
49. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction. Circulation. 2005;112:I-178-83.
50. Ruan W, Pan CZ, Huang GQ, Li YL, Ge JB, Shu XH. Assessment of left ventricular segmental function after autologous bone marrow stem cells transplantation in patients with acute myocardial infarction by tissue tracking and strain imaging. Chin Med J (Engl). 2005;118:1175-81. (Pubitemid 41051617)
51. Schachinger V, Erbs S, Elasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-21. (Pubitemid 44427445)
52. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail. 2010;3:89-96.
53. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Eng J Med. 2006;355:1199-209. (Pubitemid 44427444)
54. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113-21. (Pubitemid 43077127)
55. Huikuri HV, Kervinen K, Niemala M, et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur Heart J. 2008;29:2723-32.
56. Krause K, Jaquet K, Schneider C, et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart. 2009;95:1145-52.
57. Tendera M, Wojakowski W, Ruzytto W, et al. Intracoronary infusion of bone marrow-derived selected CD34 + CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J. 2009;30:1313-21.
58. Gyongyosi M, Lang I, Dettke M, et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomised study. Nat Clin Pract Cardiovasc Med. 2009;6:70-81.
59. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-86.
60. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTime randomized trial. JAMA. 2011;306:2110-9.
61. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:539-40.
62. Osiris Therapeutics. Prochymal significantly reduces hypertrophy, arrhythmia and progression to heart failure in patients suffering a heart attack. July 2 2012. Available at: http://www.osiris.com/pdf/2012-07- 02%20Interim%20Cardiac%20Results.pdf Accessed April 21, 2013.
63. Traverse JH, Henry TD, Vaughan DE, et al. Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells following acute myocardial infarction. Am Heart J. 2009;158:356-63.
64. Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;1-10.
65. Surder D. Intracoronary infusion of BM-MNC early or late after AMI- 4 months results of the SWISS-AMI trial: 2012 Scientific sessions of the AHA- late breaking trials. November 2012. Available at: http://my.americanheart.org/idc/ groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm-446442.pdf Accessed April 21, 2013.
66. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003;361:47-9. (Pubitemid 36050963)
67. Fuchs S, Satler LF, Kornowski R, et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. J Am Coll Cardiol. 2003;41:1721-4. (Pubitemid 36584242)
68. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-302. (Pubitemid 36578498)
69. Stamm C, Kleine HD, Westphal B, et al. CABG and bone marrow stem cell transplantation after myocardial infarction. Thorac Cardiovasc Surg. 2004;52:152-8. (Pubitemid 38832922)
70. Erbs S, Linke A, Adams V, et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion. Circ Res. 2005;97:756-62. (Pubitemid 41447125)
71. Patel AN, Geffner L, Vina RF, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study. J Thoarc Cardiovasc Surg. 2005;130:1631-8. (Pubitemid 41676929)
72. Strauer BE, Brehm M, Zeus T, et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: The IACT Study. J Am Coll Cardiol. 2005;46:1651-8. (Pubitemid 41531618)
73. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Eng J Med. 2006;355:1222-32. (Pubitemid 44427446)
74. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation. 2006;114:I-101-7. (Pubitemid 44297136)
75. Tse HF, Thambar S, Kwong YL, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J. 2007;28:2998-3005. (Pubitemid 350262782)
76. Ang KL, Chin D, Leyva F, et al. Randomized controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium. Nat Clin Pract Cardiovasc Med. 2008;5:663-70.
77. Yao K, Huang R, Qian J, et al. Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function. Heart. 2008;94:1147-53.
78. Dib N, Dinsmore J, Lababidi Z, et al. One-year follow-up of feasibility and safety of the first U.S., randomized controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). J Am Coll Cardiol Intv. 2009;2:9-16.
79. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail. 2010;12:721-9.
80. Gutierrez E, Sanz-Ruiz R, Alvarez EV, et al. General overview of the seventh international symposium on stem cell therapy and cardiovascular innovations. J Cardiovasc Transl Res. 2011;4:115-20.
81. Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-36.
82. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-57.
83. Bolli R, Chugh A, D'Amario D, et al. Effect of cardiac stem cells in patients with ischemic cardiomyopathy: Interim results of the SCIPIO Trial up to 2 years after therapy [abstract]. Late-breaking clinical trials: Cell-based therapies for myocardial regeneration. November 2012. Available at http://newsroom.heart.org/pr/aha/document/LBCT05-05-SCIPIO-abstract.pdf Accessed April 21, 2013.
84. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet. 2012;379:895-904.
85. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN Trial. JAMA. 2012;307:1717-26.
86. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON Randomized Trial. JAMA. 2012;1-11.
87. Seth S, Narang R, Bhargava B, et al. Percutaneous intracoronary cellular cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) Trial. J Am Coll Cardiol. 2006;48:2350-1. (Pubitemid 44855430)
88. Fischer-Rasokat U, Assmus B, Seeger FH, et al. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy. Circulation. 2009;2:417-23.
89. Barts & The London NHS Trust. Bone marrow derived adult stem cells for acute anterior myocardial infarction (REGEN-AMI). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT00765453? term=nct00765453&rank=1 NLM Identifier: NCT00765453.
90. Angioblast Systems. Safety study of allogeneic mesenchymal precursor cells (MPCs) in subjects with recent acute myocardial infarction. In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/ show/NCT00555828?term=nct00555828&rank=1 NLM Identifier: NCT00555828.
91. Osiris Therapeutics. Prochymal (human adult stem cells) intravenous infusion following acute myocardial infarction (AMI). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT00877903? term=nct00877903&rank=1 NLM Identifier: NCT00877903.
92. Cytori Therapeutics. Safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (ADVANCE). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT01216995?term= nct01216995&rank=1 NLM Identifier: NCT01216995.
93. Barts & The London NHS Trust. BAMI. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all cause mortality in acute myocardial infarction. In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT01569178?term= BAMI+trial&rank=1 NLM Identifier: NCT01569178.
94. Capricor Inc. Allogeneic heart stem cells to achieve myocardial regeneration (ALLSTAR). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT01458405?term=nct01458405&rank=1 NLM Identifier: NCT01458405.
95. Cedars-Sinai Medical Center. Randomized evaluation of intracoronary transplantation of bone marrow stem cells in myocardial infarction (REVITALIZE). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials. gov/ct2/show/NCT00874354?term=nct00874354&rank=1 NLM Identifier: NCT00874354.
96. Miltenyi Biotec GmbH. Intramyocardial transplantation of bone marrow stem cells in addition to coronary artery bypass graft (CABG) surgery (PERFECT). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials. gov/ct2/show/NCT00950274?term=nct00950274&rank=1 NLM Identifier: NCT00950274.
97. Barts & The London NHS Trust. Bone marrow derived adult stem cells for chronic heart failure (REGEN-IHD). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT00747708?term= nct00747708&rank=1 NLM Identifier: NCT00747708.
98. Centre hospitalier de l'Universite de Montreal (CHUM). IMPACT-CABG Trial: Implantation of autologous CD133+ stem cells in patients undergoing CABG. In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/ show/NCT01033617?term=nct01033617&rank=1 NLM Identifier: NCT01033617.
99. Juventas Therapeutics, Inc. Study to evaluate the safety and efficacy of JVS-100 administered to adults with ischemic heart failure. (STOP-HF). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/ show/NCT01643590?term=stop-hf&rank=2 NLM Identifier: NCT01643590.
100. Barts & The London NHS Trust. Bone marrow derived adult stem cells for dilated cardiomyopathy (REGENERATE-DCM). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT01302171?term= nct01302171&rank=1 NLM Identifier: NCT01302171.
101. Johann Wolfgang Goethe University Hospitals. Long-term evaluation of patients receiving bone marrow-derived cell administration for heart disease (BMC registry). In: ClinicalTrials gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 April 21]. Available from: http://www.ClinicalTrials.gov/ct2/show/NCT00962364?term=nct00962364&rank=1 NLM Identifier: NCT00962364.